Veeva Commercial Summit is one of the largest industry events in North America for commercial and medical affairs leaders.

Three Motley Fool contributors think they've found no-brainer healthcare stocks to buy in May. Here's why they picked Eli ...

Privately-held Alchemab Therapeutics, a biotech that uses the power of human immune evolution to identify and develop ...

President Trump recently warned big drugmakers that a pharmaceutical "tariff wall" is coming. Investors often view ...

Eli Lilly shares dropped Thursday as Novo Nordisk notched a coverage win for its obesity drug, a sign of the competition in ...

Eli Lilly (LLY) stock dips as CVS Health (CVS) limits access to its weight loss drug Zepbound in favor of Novo Nordisk's (NVO ...

Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template ...

Eli Lilly and Company's stock fell over 11% after CVS Caremark excluded Lilly’s obesity drug Zepbound from its standard commercial formularies starting July 1, 2025. The market overreacted to ...

Explore how Eli Lilly’s strong Q1 performance reflects ongoing trends within the S&P 500. The company’s alignment with ...

Eli Lilly’s LLY first-quarter revenue grew 45 ... CVS announcement highlights concerns that Novo could remain a strong commercial competitor in obesity. During the first quarter, Zepbound showed ...

Eli Lilly's first-quarter revenue grew 45% as ... highlights concerns that Novo Nordisk could remain a strong commercial competitor in obesity. During the first quarter, Zepbound showed even ...

The Indianapolis-based drugmaker also reaffirmed its 2025 revenue guidance but noted that the calculation was based on ...